Clinical trials: Neoplasm, Oral
Bladder Cancer, Cervical Cancer
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00666978
- Testing
- smoking cessation intervention, bupropion hydrochloride, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 540 people
- Sponsor
- Lisa Sanderson Cox, PhD
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor…
- Trial name
- NCT04505826
- Testing
- OP-1250
- Where
- 19 sites in United States, Australia
- Volunteers
- 153 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Head Neck Cancer, Oral Cancer
Newer Therapeutic Targets in Head and Neck Cancers
Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: 1.
- Trial name
- NCT05382585
- Testing
- Next generation Sequencing
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Banaras Hindu University
Breast Cancer Metastatic
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
This is a randomized, 2-arm, open-label, multicenter, international phase II trial. A total of 196 patients will be included. The study will include patients with metastatic Hormone Receptor positive / Human Epidermal Growth…
- Trial name
- PASIPHAE (NCT03322215)
- Testing
- Palbociclib, Fulvestrant, Capecitabine
- Where
- 9 sites in Sweden, United Kingdom
- Volunteers
- 42 people
- Sponsor
- Theodoros Foukakis
Head and Neck Cancer
Anti-OX40 Antibody in Head and Neck Cancer Patients
The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT02274155
- Testing
- Anti-OX40 antibody administration, Surgical Resection
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Providence Health & Services
Acute Myeloid Leukemia
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or…
- Trial name
- NCT02335814
- Testing
- FLX925
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Oral Cancer, Smoking
Prevention of Oral DNA Damage by Black Raspberries
The purpose of this voluntary research study is to learn about the potential effects that black raspberry (BRB) lozenges may have on reducing the damage caused from cigarette smoke in mouth cells in adult smokers, which may be…
- Conditions
- Oral Cancer, Smoking, DNA Damage, Oxidative Stress
- Trial name
- NCT04372914
- Testing
- BRB Lozenges
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Leukemia
Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in…
- Trial name
- NCT00262743
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Thyroid Cancer
The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer
The purpose of this study is to determine whether the use of honey mouthwashes in the prevention of salivary side effects of 131I (radioiodine) therapy.
- Trial name
- NCT01833650
- Testing
- thymus honey mouthwash
- Where
- Cyprus
- Volunteers
- 120 people
- Sponsor
- Cyprus University of Technology
Salivary Gland Neoplasms
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
To explore the feasibility, efficacy and safety of determining the treatment regimen based on genomic profiling in patients with locally advanced and advanced salivary gland cancer.
- Trial name
- MAPS (NCT05087706)
- Testing
- Pyrotinib, Bicalutamide, Leuprorelin
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Prostate Cancer
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who…
- Trial name
- NCT02445976
- Testing
- Seviteronel: given orally once daily in 28-day cycles
- Where
- 21 sites in United States
- Volunteers
- 197 people
- Sponsor
- Innocrin Pharmaceutical
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma
- Trial name
- NCT02893917
- Testing
- Cediranib, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Glioblastoma
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
This phase IV trial compares patient satisfaction with telehealth versus in-person neuro-oncology assessments among glioma patients receiving oral chemotherapy.
- Conditions
- Astrocytoma, IDH-Mutant, Glioblastoma, Glioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
- Trial name
- NCT06625047
- Testing
- Assessment, Questionnaire Administration, Telemedicine Visit
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Neoplasms, Colorectal, Solid Tumor
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Conditions
- Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
- Trial name
- SYLVER (NCT06710847)
- Testing
- GSK4418959, PD-1 inhibitor
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that…
- Conditions
- Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer
- Trial name
- NCT06997068
- Testing
- Celecoxib, Erlotinib Hydrochloride, Imaging Procedure
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Oral Mucositis
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
- Trial name
- NCT02013050
- Testing
- SGX942
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Soligenix
Polycystic Ovary Syndrome
Effects of Metformin and Oral Hormonal Contraceptive in Adolescents With Polycystic Ovary Syndrome
The polycystic ovary syndrome is the most common endocrinopathy in reproductive age women. The pathophysiology of this syndrome remains unclear, but there are evidences that a decreased in insulin sensitivity may be related in…
- Trial name
- NCT00988078
- Testing
- Metformin
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Oral Cancer
Using an APP in Post Oral Cancer Surgery to Affect Patients' Needs and Quality of Life.
This study aimed to explore using an APP in post oral cancer surgery to affect patients' needs and quality of life. Methods Quasi-experimental Research Design used purposeful sampling from January 1 to December 31 of the Far…
- Trial name
- NCT04049968
- Testing
- Mobile health application (APP), Routine health care and instruction
- Volunteers
- 100 people
- Sponsor
- Far Eastern Memorial Hospital
Kaposi´s Sarcoma
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed.
- Trial name
- NCT01296815
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.